QUE ONCOLOGY
QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) research commercialization company, UniQuest, in Brisbane, Australia. QUE licenses intellectual property originating from research discoveries at both UQ and Emoryโs Institute for Drug Development (EIDD). The leading drug candidate is Q-122, a compound with anti-inflammatory properties that is in Phase 1b clinical development for the treatment of hot flashes in women with breast cancer who are receiving anti-estrogen therapy. Additional cancer research projects that have been identified to supply the QUE Oncology pipeline are designed to address prostate cancer, breast cancer, melanoma, and cancer pain.
QUE ONCOLOGY
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2012-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.queoncology.com
Total Employee:
11+
Status:
Active
Total Funding:
16.52 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail Google Cloud
Current Employees Featured
Founder
Investors List
Uniseed Ventures
Uniseed Ventures investment in Series A - QUE Oncology
Stoic VC
Stoic VC investment in Series A - QUE Oncology
Brandon Capital Partners
Brandon Capital Partners investment in Series A - QUE Oncology
Georgia Research Alliance
Georgia Research Alliance investment in Grant - QUE Oncology
Georgia Research Alliance
Georgia Research Alliance investment in Grant - QUE Oncology
Georgia Research Alliance
Georgia Research Alliance investment in Grant - QUE Oncology
Georgia Research Alliance
Georgia Research Alliance investment in Grant - QUE Oncology
Georgia Research Alliance
Georgia Research Alliance investment in Grant - QUE Oncology
Georgia Research Alliance
Georgia Research Alliance investment in Grant - QUE Oncology
Official Site Inspections
http://www.queoncology.com Semrush global rank: 5.91 M Semrush visits lastest month: 1.4 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "QUE Oncology"
HOME | queoncology
Developing novel . non-hormonal therapies to address moderate to severe vasomotor symptoms in postmenopausal women, and in cancer patients receiving hormone therapy.See details»
ABOUT QUE - queoncology
QUE Oncology is focused on unlocking the significant potential of its lead product Q-122 in development as a non-hormonal treatment for moderate to severe vasomotor symptoms (hot โฆSee details»
QUE Oncology - Crunchbase Company Profile & Funding
QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) โฆSee details»
Board of Directors - queoncology
Dennis Liotta, PhD . Over the past three decades Dr. Dennis Liottaโs research has focused on the discovery and development of novel antiviral, anticancer and anti-inflammatory therapeutic agents.See details»
QUE ONCOLOGY PTY LTD - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for QUE ONCOLOGY PTY LTD of Melbourne, VICTORIA. Get the latest business insights from Dun & โฆSee details»
QUE Oncology - Org Chart, Teams, Culture & Jobs
View QUE Oncology's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
QUE Oncology 2025 Company Profile: Valuation, โฆ
QUE Oncology General Information Description. Developer of novel non-hormonal therapies designed to address moderate to severe vasomotor symptoms. The company's orally bioavailable, non-hormonal, small molecule โฆSee details»
QUE Oncology - VentureRadar
QUE Oncology is a drug discovery company developing novel drug candidates to treat cancer and its consequences, from an early development stage to the end of Phase II clinical trials, at โฆSee details»
QUE Oncology - Uniseed
Website: www.queoncology.com QUE Oncology, Inc. (QUE) was formed in 2013 through a collaboration between Emory Universityโs Institute for Drug Development (EIDD), in Atlanta, โฆSee details»
QUE Oncology - Startup Galaxy
QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) research commercialization โฆSee details»
QUE Oncology : MTPConnect
About QUE Oncology. QUE Oncology is a privately held Melbourne-based clinical stage biotech company focused on innovative medicines to improve the tolerability of current anti-cancer โฆSee details»
QUE Oncology - Craft
QUE Oncology is a company developing drugs to address medical needs associated with women's health conditions. It provides Q-122, an orally available small molecule for the โฆSee details»
QUE Oncology - Contacts, Employees, Board Members
QUE Oncology develops novel therapies to address unmet medical needs in the treatment of cancer and its consequences.See details»
QUE Oncology - Overview, News & Similar companies - ZoomInfo
Apr 2, 2019 www.queoncology.com. Revenue $5.5 Million. Industry Manufacturing General Manufacturing . Recent News & Media. QUE Oncology's non-hormonal therapy reduces hot โฆSee details»
QUE Oncology CEO, Founder, Key Executive Team, Board of โฆ
Explore {QUE Oncology's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
THE TEAM | queoncology
© 2022 | QUE Oncology. bottom of pageSee details»
Que Oncology - Brandon BioCatalyst
QUE Oncology is a clinical stage company focussed on developing Q-122 for the treatment of hot flashes in cancer survivors undergoing endocrine therapy.See details»
QUE Oncology Inc (QUE Oncology Inc) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer โฆSee details»
Q-122 - queoncology
Q-122 is an orally bioavailable, non-hormonal, small molecule that is being developed by QUE Oncology as a treatment for vasomotor symptoms (VMS; also known as hot flashes and night โฆSee details»
QUE Oncology's non-hormonal therapy reduces hot flushes and โฆ
MELBOURNE, Australia, Nov. 10, 2022 /PRNewswire/ -- QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy for the treatment of vasomotor โฆSee details»